3 Athira Pharma (ATHA) KOLs Are Positive on ATH-1017 Data Ahead of PDUFA, Jefferies Reiteates Buy
Tweet Send to a Friend
Jefferies analyst Andrew Tsai reiterated a Buy rating and $40.00 price target on Athira Pharma (NASDAQ: ATHA) after speaking with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
